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phase II in fixed effect regression models to estimate the ef-
fect of incontinence on caring costs for UI.
RESULTS: Compared with long-term care residents with-
out UI, those with occasional UI consumed $2.90 more
per shift on labor and supply costs, while those with fre-
quent UI consumed $5.76 more. Incremental laundry costs
per shift are $0.34. Our study suggests that, on average,
the increased cost of caring for a UI patient in a long term
care facility is $5,650 per year, after controlling for factors
such as patient demographics, insurance status, type of
long-term care, and shift.
CONCLUSIONS: Behavioral, pharmacological, and medi-
cal treatments that successfully control or alleviate UI condi-
tions may yield substantial savings in long-term care set-
tings.
ECONOMIC AND OUTCOMES ISSUES OF 
INFECTIOUS DISEASES
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OBJECTIVES: To estimate the indirect costs of HIV and
AIDS for individuals in the United Kingdom based on uti-
lization of informal (non-medical) care and community
services; to compare these figures with direct costs; and to
demonstrate the multitude of budgets that are affected by
indirect costs.
METHODS: A prevalence-based model was used to deter-
mine the aggregate utilization by stage of progression (as-
ymptomatic HIV, symptomatic non-AIDS, AIDS). Sources
of data included SOPHID97 for prevalence figures; pub-
lished data by Petrou, et al. on service utilization and costs;
published figures from Lubeck and Fries and data from the
Positive Lives Employment Survey 1997 for disability; and
the UK Office of National Statistics Family Expenditure
Survey 1997–98 for disability and income data.
RESULTS: Annual indirect costs (converted to 1998 British
pounds) are £3,881.14 for asymptomatic HIV patients;
£7,865.17 for symptomatic non-AIDS patients; and
£21,695.13 for AIDS patients. These figures can be com-
pared to annual hospital direct cost figures published in
PharmacoEconomics in 1998, which were £2,391 for as-
ymptomatic HIV patients; £4,562 for symptomatic non-
AIDS patients; and £15,895 for AIDS patients. Thus, our
estimates of indirect costs are higher than the hospital direct
cost estimates for all three groups of HIV/AIDS patients.
CONCLUSIONS: The difference (in 1998 British pounds)
in annual indirect costs per patient between asymptomatic
and symptomatic non-AIDS patients is £3,984.03. The dif-
ference in annual indirect costs per patient between symp-
tomatic non-AIDS and AIDS patients is £13,829.96. These
differences demonstrate the potential for significant savings
if disease progression can be prevented or delayed. Focus on
indirect costs of HIV/AIDS demonstrates the complexity of
decision making when data is limited to direct medical costs
and raises an issue regarding who should have input into de-
cision making when multiple budgets are affected.
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OBJECTIVES: Lyme disease is an increasingly common
condition in the United States and temperate regions of
Europe and Asia. The reported cases have increased 25
fold since 1982. Recently two vaccines have been devel-
oped. Decisions about the cost effectiveness require consis-
tent cost estimates. The objective of this study is to identify
the costs of diagnosis, treatment, treatment failure, and
late diagnosis in a large HMO population located in an en-
demic area. Prior studies have not included the worried
well who are tested but do not receive treatment.
METHODS: This study is a matched retrospective cohort
study. 8,017 individuals tested or diagnosed with LD was
matched by age, gender, and zip code with a control popu-
lation. Standardized HMO and pharmacy costs were gath-
ered from the HMO claims system. Chronic disease status
was controlled using the Chronic Disease Score. Costs
were assessed for six weeks prior to first LD contact and
six weeks following first LD contact. Late-effect and treat-
ment failures were assessed separately for longer post-con-
tact windows. 
RESULTS: The mean 12 week per capita medical direct
expense for LD cases is 4.1 times higher than for the con-
trol group. The cost difference is highly significant (p 
0.001). Pharmacy expense is 1.77 times greater (p 
0.001).
CONCLUSIONS: The cost effectiveness of LD vaccines is
dependent on the identifying the cost of both treatment
and anxiety caused by the potential of tick-borne infec-
tion. The costs differences illustrated in this study empha-
size the importance of both true positives and the “wor-
ried-well” in assessing the total cost of LD to health
insurance sponsors.
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OBJECTIVES: The objective of this study was to measure
influenza-related hospitalization rates and cost in a man-
aged care population.
